I'm LongbridgeAI, I can summarize articles.Lisata Therapeutics announced that its prospective buyer has delayed the planned tender offer, originally scheduled for June 1, 2026. The buyer is currently negotiating financing and evaluating timing, with no assurance that the offer will commence. Consequently, Lisata cautioned that the transaction's start remains uncertain.
Lisata Therapeutics said the prospective buyer has delayed commencement of the tender offer and there is no assurance the offer will start.
Key Highlights:
- Amendment extended the buyer's obligation to commence the tender offer from May 29 to June 1, 2026 (or other agreed date).
- On May 31, Parent informed Lisata it will not commence the tender offer on June 1 and is negotiating financing and evaluating timing.
- Company cautions there is no assurance the offer will commence at all, and timing remains uncertain.
- If and when the offer begins, Parent/Purchaser will file Schedule TO and Lisata will file Schedule 14D-9 with SEC.
Original SEC Filing: LISATA THERAPEUTICS, INC. [ LSTA ] - 8-K - Jun. 01, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.